# 90_CROSS-SESSION-LOG — safety-pharmacology-intelligence (2026-09-01-v1)

Append-only control-plane message log for this role. Full research content lives in this role's
owned `10_DATA/`/`20_EVIDENCE/`/`30_METHODS/` paths, not here.

---

## 2026-09-01 — Resume + Wave 1 dispatch

Received `TASK_ASSIGNMENT` for the new additive run. Initially could not locate
`research/pitavastatin-ezetimibe-evidence/2026-09-01-v1/` anywhere (own worktree, origin/main, or any
pushed remote branch) — reported `BLOCKED_FOR_SOURCE` rather than guess at charter content. Director
clarified it's local-only in their own linked git worktree (`worktree-pit-eze-run-2026-09-01`, no
push per PI instruction) and pointed to `git show <branch>:<path>` as a same-repo, no-fetch-needed
read path. Verified this worked, read all six governance files (00-05) via that method, confirmed
Focus Area 4 (defensible clinical positioning) matches the task assignment. Flagged one minor
staleness in `05_STATUS.md` (Gate 0 wording not updated after the dispatch commit) — non-blocking,
noted for whenever convenient, same category as a similar catch in the prior run.

Created a local branch (`worktree-safety-pharm-2026-09-01`) based on the Director's dispatch commit,
inside this same isolated worktree, to write this role's own output without touching the Director's
branch directly.

## 2026-09-01 — Wave 1 work

Produced `positioning-brief.md` (Focus Area 4: FDC vs pitavastatin monotherapy / vs high-intensity
statin monotherapy / vs other nonstatin add-ons, carrying forward the prior run's Wave-4-audited
evidence with new claim-safe taxonomy tags applied) and `attack-defense-contribution.md` (Focus Area
5: honest limits of the diabetes/DDI positioning, three specific safety/DDI-grounds scenarios where
bempedoic acid/PCSK9-targeting therapy/inclisiran may be more defensible, and a cost/adherence-
realistic counter-view). Ran a light (non-exhaustive) fresh search given the reduced tool
connectivity this session (paper-search/tavily/openevidence down; research_hub/google-scholar/
WebFetch available) — found one DOI completion for an already-known source (K-924, no new content)
and one title-only unverified candidate (AJBR 2024 diabetes-specific paper, 403 on abstract fetch,
no content cited). No contradictions or material new findings versus the prior run's audited base.

Full detail in `30_METHODS/safety-pharmacology/search-log.md` and the two evidence files above.
